AGC acquires a leading German biopharmaceutical CMO
Biomeva, a reliable and experienced CMO in the biopharmaceutical industry, is dedicated to meeting the manufacturing needs for the production of microbially expressed protein products
AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announces that it has acquired all of the shares of Biomeva GmbH (Biomeva) from Biomeva Holding GmbH.
Biomeva is one of the leading biopharmaceutical contract manufacturing organisations (CMOs) in Europe. With Biomeva now a part of the AGC Group, AGC’s Life Science Business will be offering wider geographic coverage and a wider range of capacities.
Based in the Bio Cluster City of Heidelberg, Germany, Biomeva has almost 25 years of experience in providing contract development and manufacturing services using microbial expression technology to European and other International customers.
Biomeva’s services include process development for highly efficient therapeutic protein expression, cGMP-compliant fermentation, purification and bulk filling, as well as analytical testing and cell banking.
Dr Thomas Pultar, CEO of Biomeva, said: 'By combining Biomeva’s capabilities and AGC’s large-scale manufacturing capacities, we will generate a new and strong international microbial CMO, offering the complete services from process development to large-scale market supply. To me, this is a perfect synergy between Biomeva’s strength in clinical manufacturing and AGC’s expertise and capacity for commercial production. I look forward to continuing my role as CEO of Biomeva under this new ownership.'
Under the management policy, AGC plus, the AGC Group has designated Life Science Business as one of its strategic areas. The synergy generated through the business integration of AGC and Biomeva being an important addition, the AGC Group is dedicated to speeding up and expanding its biopharmaceutical contract services business.
